PURPOSE: Deregulation of the retinoblastoma (RB) pathway is commonly found in virtually all known human tumors. p16, the upstream regulator of RB, is among the most commonly affected member of this pathway. In the present study, we examined the prognostic value of p16 expression in men with locally advanced prostate cancer who were enrolled on Radiation Therapy Oncology Group protocol 9202. PATIENTS AND METHODS: RTOG 9202 was a phase III randomized study comparing long-term (LT) versus short-term (ST) androgen-deprivation therapy (AD). Of the 1,514 eligible cases, 612 patients had adequate tumor material for p16 analysis. Expression levels of p16 were determined by immunohistochemistry (IHC). IHC staining was scored quantitatively using an image analysis system. RESULTS: On multivariate analysis, intact p16 expression was significantly associated with decreased rate of distant metastases (P = .0332) when both STAD and LTAD treatment arms were considered together. For patients with intact (high levels of immunostaining) p16 (mean p16 index > 81.3%), LTAD plus radiotherapy (RT) significantly improved prostate cancer survival (PCS) compared with STAD plus RT (P = .0008) and reduced the frequency of distant metastasis (P = .0069) compared with STAD plus RT. In contrast, for patients with tumors demonstrating p16 loss (low levels of immunostaining, mean p16 index < or = 81.3%), LTAD plus RT significantly improved biochemical no evidence of disease survival over STAD (P < .0001) primarily by decreasing the frequency of local progression (P = .02), as opposed to distant metastasis, which was the case in the high-p16 cohort. CONCLUSION: Low levels of p16 on image analysis appear to be associated with a significantly higher risk of distant metastases among all study patients. p16 expression levels also appear to identify patients with locally advanced prostate cancer with distinct patterns of failure after LTAD.
RCT Entities:
PURPOSE: Deregulation of the retinoblastoma (RB) pathway is commonly found in virtually all known humantumors. p16, the upstream regulator of RB, is among the most commonly affected member of this pathway. In the present study, we examined the prognostic value of p16 expression in men with locally advanced prostate cancer who were enrolled on Radiation Therapy Oncology Group protocol 9202. PATIENTS AND METHODS: RTOG 9202 was a phase III randomized study comparing long-term (LT) versus short-term (ST) androgen-deprivation therapy (AD). Of the 1,514 eligible cases, 612 patients had adequate tumor material for p16 analysis. Expression levels of p16 were determined by immunohistochemistry (IHC). IHC staining was scored quantitatively using an image analysis system. RESULTS: On multivariate analysis, intact p16 expression was significantly associated with decreased rate of distant metastases (P = .0332) when both STAD and LTAD treatment arms were considered together. For patients with intact (high levels of immunostaining) p16 (mean p16 index > 81.3%), LTAD plus radiotherapy (RT) significantly improved prostate cancer survival (PCS) compared with STAD plus RT (P = .0008) and reduced the frequency of distant metastasis (P = .0069) compared with STAD plus RT. In contrast, for patients with tumors demonstrating p16 loss (low levels of immunostaining, mean p16 index < or = 81.3%), LTAD plus RT significantly improved biochemical no evidence of disease survival over STAD (P < .0001) primarily by decreasing the frequency of local progression (P = .02), as opposed to distant metastasis, which was the case in the high-p16 cohort. CONCLUSION: Low levels of p16 on image analysis appear to be associated with a significantly higher risk of distant metastases among all study patients. p16 expression levels also appear to identify patients with locally advanced prostate cancer with distinct patterns of failure after LTAD.
Authors: D F Jarrard; G S Bova; C M Ewing; S S Pin; S H Nguyen; S B Baylin; P Cairns; D Sidransky; J G Herman; W B Isaacs Journal: Genes Chromosomes Cancer Date: 1997-06 Impact factor: 5.006
Authors: Ali Namazie; Sassan Alavi; Olufunmilayo I Olopade; Giovanni Pauletti; Neema Aghamohammadi; M Aghamohammadi; Jeffrey A Gornbein; Thomas C Calcaterra; Dennis J Slamon; Marilene B Wang; Eri S Srivatsan Journal: Laryngoscope Date: 2002-03 Impact factor: 3.325
Authors: M V Pilepich; J M Krall; M al-Sarraf; M J John; R L Doggett; W T Sause; C A Lawton; R A Abrams; M Rotman; P Rubin Journal: Urology Date: 1995-04 Impact factor: 2.649
Authors: A Chakravarti; K Heydon; C L Wu; E Hammond; A Pollack; M Roach; H Wolkov; P Okunieff; J Cox; J Fontanesi; R Abrams; M Pilepich; W Shipley Journal: J Clin Oncol Date: 2003-09-01 Impact factor: 44.544
Authors: Gerald E Hanks; Thomas F Pajak; Arthur Porter; David Grignon; Harmart Brereton; Varagur Venkatesan; Eric M Horwitz; Colleen Lawton; Seth A Rosenthal; Howard M Sandler; William U Shipley Journal: J Clin Oncol Date: 2003-11-01 Impact factor: 44.544
Authors: Teodora Niculescu; Susanna Weerth; Lucian Soane; Florin Niculescu; Violeta Rus; Cedric S Raine; Moon L Shin; Horea Rus Journal: Ann N Y Acad Sci Date: 2003-12 Impact factor: 5.691
Authors: Alan Pollack; James J Dignam; Dayssy A Diaz; Qian Wu; Radka Stoyanova; Kyounghwa Bae; Adam P Dicker; Howard Sandler; Gerald E Hanks; Felix Y Feng Journal: Clin Cancer Res Date: 2014-10-07 Impact factor: 12.531
Authors: Alan Pollack; Deukwoo Kwon; Gail Walker; Li Yan Khor; Eric M Horwitz; Mark K Buyyounouski; Radka Stoyanova Journal: J Natl Cancer Inst Date: 2017-02-01 Impact factor: 13.506
Authors: Christoph Burdelski; Tatsiana Dieckmann; Asmus Heumann; Claudia Hube-Magg; Martina Kluth; Burkhard Beyer; Thomas Steuber; Raisa Pompe; Markus Graefen; Ronald Simon; Sarah Minner; Maria Christina Tsourlakis; Christina Koop; Jakob Izbicki; Guido Sauter; Till Krech; Thorsten Schlomm; Waldemar Wilczak; Patrick Lebok Journal: Tumour Biol Date: 2016-07-21
Authors: Ettickan Boopathi; Steve Ciment; Chellappagounder Thangavel; Yi Liu; Raymond O'Neill; Ankur Sharma; Steve B McMahon; Hestia Mellert; Sankar Addya; Adam Ertel; Ruth Birbe; Paolo Fortina; Adam P Dicker; Karen E Knudsen; Robert B Den Journal: Clin Cancer Res Date: 2014-08-27 Impact factor: 12.531
Authors: Li-Yan Khor; Kyounghwa Bae; Rebecca Paulus; Tahseen Al-Saleem; M Elizabeth Hammond; David J Grignon; Mingxin Che; Varagur Venkatesan; Roger W Byhardt; Marvin Rotman; Gerald E Hanks; Howard M Sandler; Alan Pollack Journal: J Clin Oncol Date: 2009-05-26 Impact factor: 44.544